Share Price and Basic Stock Data
Last Updated: November 26, 2025, 4:28 pm
| PEG Ratio | 6.60 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Apollo Hospitals Enterprise Ltd, a leading player in the Hospitals and Medical Services industry, reported a price of ₹7,396 and a market capitalization of ₹1,06,336 Cr. For the fiscal year ending March 2023, the company recorded sales of ₹16,612 Cr, reflecting a significant increase from ₹14,663 Cr in the previous fiscal year. The upward trend continued, with trailing twelve months (TTM) sales reaching ₹23,265 Cr. Quarterly sales showed consistent growth, with ₹4,944 Cr reported in March 2024 and projected sales of ₹5,842 Cr by June 2025. The operating profit margin (OPM) stood at 15% for the current fiscal year, showcasing the company’s ability to maintain profitability amidst rising revenues. The increase in sales can be attributed to the expansion of services and facilities, which have enhanced patient capacity and service offerings. Overall, Apollo Hospitals demonstrates a robust revenue trajectory, positioning itself favorably within the healthcare sector.
Profitability and Efficiency Metrics
The profitability metrics for Apollo Hospitals indicate a solid financial performance, with a reported net profit of ₹1,729 Cr and an impressive return on equity (ROE) of 18.4%. The company’s operating profit (₹2,065 Cr in FY 2023) and net profit margin, which stood at 6.75%, reflect strong operational efficiency. The interest coverage ratio (ICR) was reported at 7.03x, indicating that the company comfortably meets its interest obligations. Additionally, the cash conversion cycle (CCC) was remarkably low at -6 days, highlighting efficient working capital management. The operating profit margin (OPM) has been stable, recorded at 14% for FY 2025, with a slight increase in the upcoming quarters. However, the rising expenses, which reached ₹14,548 Cr in FY 2023, may pose challenges to sustained profitability if not managed effectively. Overall, Apollo Hospitals showcases commendable profitability and efficiency metrics, aligning well with industry standards.
Balance Sheet Strength and Financial Ratios
Apollo Hospitals’ balance sheet reflects a robust financial structure, with total assets amounting to ₹20,644 Cr as of March 2025. The company reported reserves of ₹9,021 Cr, demonstrating strong retained earnings and capital accumulation. Borrowings stood at ₹7,987 Cr, resulting in a manageable total debt to equity ratio of 0.64, indicating a balanced approach to leverage. The return on capital employed (ROCE) was reported at 17.60%, showcasing efficient utilization of capital. Furthermore, the current ratio of 1.53 indicates adequate liquidity to meet short-term obligations. The price-to-book value (P/BV) ratio stood at 11.60x, suggesting that investors are willing to pay a premium for the company’s earnings potential. While the financial ratios favorably position Apollo Hospitals within the sector, the increasing debt levels warrant close monitoring to prevent potential financial strain amidst expanding operations.
Shareholding Pattern and Investor Confidence
The shareholding structure of Apollo Hospitals reflects a diversified ownership base, with promoters holding 28.02% and foreign institutional investors (FIIs) accounting for 44.20%. Domestic institutional investors (DIIs) hold 21.12%, while public ownership stands at 6.43%. The number of shareholders has increased to 1,60,556, indicating growing investor interest and confidence in the company. Over the past year, promoter holdings have seen a slight decline from 29.33% to 28.02%, which may raise questions about long-term commitment. However, the substantial presence of FIIs suggests strong international confidence in Apollo’s growth prospects. The stability in DIIs’ holdings at around 21% further reinforces trust in the company’s operational strategy. Overall, the shareholding pattern indicates a balanced investment appeal, although the declining promoter stake could be a point for potential investor scrutiny.
Outlook, Risks, and Final Insight
Apollo Hospitals is poised for continued growth, driven by its expanding service capabilities and increasing patient volumes. The positive revenue trends and strong profitability metrics suggest a favorable operational outlook. However, potential risks include rising operational costs and increasing debt levels, which could impact profitability if not managed prudently. Moreover, competition within the healthcare sector is intensifying, which could pressure margins. The company must focus on sustaining its operational efficiency and managing costs effectively to mitigate these risks. Should Apollo Hospitals successfully navigate these challenges, it can capitalize on the growing demand for healthcare services in India. Conversely, failure to address these risks could hinder growth and erode investor confidence. Overall, Apollo Hospitals presents a compelling investment opportunity, albeit with caution warranted due to potential operational challenges.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Apollo Hospitals Enterprise Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 43.3 Cr. | 129 | 195/125 | 8.84 | 117 | 2.71 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 20.2 Cr. | 19.2 | 35.5/18.3 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 12.1 Cr. | 11.7 | 21.4/11.6 | 134 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 118 Cr. | 62.8 | 98.7/53.3 | 26.0 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.8 Cr. | 3.85 | 7.60/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 27,966.64 Cr | 838.28 | 99.60 | 102.21 | 0.28% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,796 | 4,251 | 4,264 | 4,302 | 4,418 | 4,847 | 4,851 | 4,944 | 5,086 | 5,589 | 5,527 | 5,592 | 5,842 |
| Expenses | 3,317 | 3,699 | 3,780 | 3,814 | 3,909 | 4,219 | 4,237 | 4,303 | 4,410 | 4,774 | 4,765 | 4,822 | 4,990 |
| Operating Profit | 479 | 552 | 484 | 488 | 509 | 628 | 614 | 640 | 675 | 816 | 762 | 770 | 852 |
| OPM % | 13% | 13% | 11% | 11% | 12% | 13% | 13% | 13% | 13% | 15% | 14% | 14% | 15% |
| Other Income | 16 | 23 | 35 | 20 | 34 | 26 | 29 | 37 | 49 | 44 | 69 | 72 | 54 |
| Interest | 93 | 93 | 100 | 95 | 106 | 111 | 113 | 119 | 116 | 118 | 110 | 115 | 108 |
| Depreciation | 148 | 155 | 153 | 159 | 167 | 163 | 167 | 190 | 177 | 184 | 185 | 211 | 215 |
| Profit before tax | 254 | 327 | 266 | 254 | 270 | 379 | 363 | 368 | 430 | 557 | 536 | 516 | 583 |
| Tax % | -27% | 35% | 39% | 43% | 36% | 34% | 30% | 30% | 27% | 29% | 29% | 20% | 24% |
| Net Profit | 324 | 213 | 162 | 146 | 173 | 249 | 254 | 258 | 316 | 396 | 379 | 414 | 441 |
| EPS in Rs | 22.06 | 14.19 | 10.68 | 10.05 | 11.59 | 16.20 | 17.06 | 17.65 | 21.23 | 26.34 | 25.89 | 27.10 | 30.10 |
Last Updated: August 20, 2025, 1:45 pm
Below is a detailed analysis of the quarterly data for Apollo Hospitals Enterprise Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 5,842.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,592.00 Cr. (Mar 2025) to 5,842.00 Cr., marking an increase of 250.00 Cr..
- For Expenses, as of Jun 2025, the value is 4,990.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,822.00 Cr. (Mar 2025) to 4,990.00 Cr., marking an increase of 168.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 852.00 Cr.. The value appears strong and on an upward trend. It has increased from 770.00 Cr. (Mar 2025) to 852.00 Cr., marking an increase of 82.00 Cr..
- For OPM %, as of Jun 2025, the value is 15.00%. The value appears strong and on an upward trend. It has increased from 14.00% (Mar 2025) to 15.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 54.00 Cr.. The value appears to be declining and may need further review. It has decreased from 72.00 Cr. (Mar 2025) to 54.00 Cr., marking a decrease of 18.00 Cr..
- For Interest, as of Jun 2025, the value is 108.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 115.00 Cr. (Mar 2025) to 108.00 Cr., marking a decrease of 7.00 Cr..
- For Depreciation, as of Jun 2025, the value is 215.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 211.00 Cr. (Mar 2025) to 215.00 Cr., marking an increase of 4.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 583.00 Cr.. The value appears strong and on an upward trend. It has increased from 516.00 Cr. (Mar 2025) to 583.00 Cr., marking an increase of 67.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 20.00% (Mar 2025) to 24.00%, marking an increase of 4.00%.
- For Net Profit, as of Jun 2025, the value is 441.00 Cr.. The value appears strong and on an upward trend. It has increased from 414.00 Cr. (Mar 2025) to 441.00 Cr., marking an increase of 27.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 30.10. The value appears strong and on an upward trend. It has increased from 27.10 (Mar 2025) to 30.10, marking an increase of 3.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:46 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,357 | 5,129 | 6,150 | 7,256 | 8,243 | 9,617 | 11,247 | 10,560 | 14,663 | 16,612 | 19,059 | 21,794 | 23,265 |
| Expenses | 3,681 | 4,392 | 5,465 | 6,522 | 7,442 | 8,548 | 9,656 | 9,420 | 12,474 | 14,548 | 16,665 | 18,761 | 19,940 |
| Operating Profit | 676 | 737 | 684 | 734 | 801 | 1,070 | 1,591 | 1,140 | 2,189 | 2,065 | 2,394 | 3,033 | 3,324 |
| OPM % | 16% | 14% | 11% | 10% | 10% | 11% | 14% | 11% | 15% | 12% | 13% | 14% | 14% |
| Other Income | 18 | 47 | 92 | 60 | 24 | 26 | 222 | 103 | 368 | 75 | 123 | 222 | 256 |
| Interest | 119 | 118 | 180 | 257 | 295 | 327 | 533 | 449 | 379 | 381 | 449 | 458 | 442 |
| Depreciation | 168 | 212 | 264 | 314 | 359 | 396 | 620 | 573 | 601 | 615 | 687 | 758 | 828 |
| Profit before tax | 407 | 455 | 332 | 222 | 171 | 373 | 660 | 221 | 1,578 | 1,144 | 1,380 | 2,039 | 2,309 |
| Tax % | 25% | 29% | 29% | 41% | 65% | 47% | 34% | 38% | 30% | 22% | 32% | 26% | |
| Net Profit | 315 | 335 | 235 | 131 | 60 | 200 | 432 | 137 | 1,108 | 844 | 935 | 1,505 | 1,729 |
| EPS in Rs | 22.77 | 24.43 | 16.99 | 15.88 | 8.44 | 16.96 | 32.70 | 10.46 | 73.42 | 56.97 | 62.50 | 100.56 | 116.28 |
| Dividend Payout % | 25% | 24% | 35% | 38% | 59% | 35% | 18% | 29% | 16% | 26% | 26% | 13% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.35% | -29.85% | -44.26% | -54.20% | 233.33% | 116.00% | -68.29% | 708.76% | -23.83% | 10.78% | 60.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | -36.20% | -14.40% | -9.94% | 287.53% | -117.33% | -184.29% | 777.05% | -732.59% | 34.61% | 50.18% |
Apollo Hospitals Enterprise Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 14% |
| 3 Years: | 14% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 34% |
| 3 Years: | 18% |
| TTM: | 52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 37% |
| 3 Years: | 23% |
| 1 Year: | 14% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 15% |
| Last Year: | 18% |
Last Updated: September 4, 2025, 11:25 pm
Balance Sheet
Last Updated: November 9, 2025, 1:38 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 72 | 72 | 72 | 72 | 72 | 72 |
| Reserves | 2,907 | 3,102 | 3,262 | 3,244 | 3,182 | 3,264 | 3,270 | 4,531 | 5,551 | 6,126 | 6,864 | 8,140 | 9,021 |
| Borrowings | 1,344 | 1,992 | 2,834 | 3,125 | 3,427 | 3,673 | 3,596 | 4,160 | 4,068 | 4,332 | 5,333 | 7,864 | 7,987 |
| Other Liabilities | 1,029 | 1,296 | 1,195 | 1,665 | 1,917 | 2,159 | 4,354 | 2,629 | 3,570 | 3,886 | 4,474 | 4,568 | 4,870 |
| Total Liabilities | 5,350 | 6,459 | 7,360 | 8,103 | 8,596 | 9,166 | 11,289 | 11,392 | 13,261 | 14,416 | 16,742 | 20,644 | 21,950 |
| Fixed Assets | 2,681 | 3,244 | 3,997 | 4,591 | 4,773 | 4,982 | 7,432 | 6,778 | 8,296 | 8,520 | 9,664 | 10,988 | 11,262 |
| CWIP | 491 | 533 | 562 | 347 | 712 | 822 | 236 | 234 | 46 | 610 | 873 | 921 | 1,026 |
| Investments | 322 | 311 | 352 | 406 | 352 | 462 | 434 | 1,343 | 816 | 574 | 986 | 2,487 | 3,008 |
| Other Assets | 1,855 | 2,372 | 2,448 | 2,759 | 2,759 | 2,901 | 3,187 | 3,037 | 4,104 | 4,712 | 5,219 | 6,248 | 6,653 |
| Total Assets | 5,350 | 6,459 | 7,360 | 8,103 | 8,596 | 9,166 | 11,289 | 11,392 | 13,261 | 14,416 | 16,742 | 20,644 | 21,950 |
Below is a detailed analysis of the balance sheet data for Apollo Hospitals Enterprise Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 72.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 72.00 Cr..
- For Reserves, as of Sep 2025, the value is 9,021.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,140.00 Cr. (Mar 2025) to 9,021.00 Cr., marking an increase of 881.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7,987.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 7,864.00 Cr. (Mar 2025) to 7,987.00 Cr., marking an increase of 123.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4,870.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,568.00 Cr. (Mar 2025) to 4,870.00 Cr., marking an increase of 302.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 21,950.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20,644.00 Cr. (Mar 2025) to 21,950.00 Cr., marking an increase of 1,306.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11,262.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,988.00 Cr. (Mar 2025) to 11,262.00 Cr., marking an increase of 274.00 Cr..
- For CWIP, as of Sep 2025, the value is 1,026.00 Cr.. The value appears strong and on an upward trend. It has increased from 921.00 Cr. (Mar 2025) to 1,026.00 Cr., marking an increase of 105.00 Cr..
- For Investments, as of Sep 2025, the value is 3,008.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,487.00 Cr. (Mar 2025) to 3,008.00 Cr., marking an increase of 521.00 Cr..
- For Other Assets, as of Sep 2025, the value is 6,653.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,248.00 Cr. (Mar 2025) to 6,653.00 Cr., marking an increase of 405.00 Cr..
- For Total Assets, as of Sep 2025, the value is 21,950.00 Cr.. The value appears strong and on an upward trend. It has increased from 20,644.00 Cr. (Mar 2025) to 21,950.00 Cr., marking an increase of 1,306.00 Cr..
Notably, the Reserves (9,021.00 Cr.) exceed the Borrowings (7,987.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 675.00 | 736.00 | 682.00 | 731.00 | 798.00 | -2.00 | -2.00 | -3.00 | -2.00 | -2.00 | -3.00 | -4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44 | 43 | 36 | 38 | 37 | 39 | 33 | 46 | 44 | 49 | 48 | 51 |
| Inventory Days | 47 | 50 | 49 | 47 | 51 | 46 | 49 | 16 | 21 | 17 | 17 | 16 |
| Days Payable | 55 | 59 | 66 | 51 | 55 | 56 | 60 | 74 | 79 | 82 | 88 | 72 |
| Cash Conversion Cycle | 36 | 34 | 19 | 34 | 33 | 29 | 22 | -12 | -14 | -16 | -23 | -6 |
| Working Capital Days | 23 | 24 | 16 | 27 | 8 | -3 | -8 | -4 | 5 | -1 | -19 | -6 |
| ROCE % | 12% | 12% | 9% | 8% | 7% | 10% | 14% | 8% | 17% | 14% | 15% | 17% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Flexi Cap Fund - Regular Plan | 3,207,166 | 4.28 | 2037.5 | 3,207,166 | 2025-04-22 17:25:42 | 0% |
| SBI Nifty 50 ETF | 1,822,347 | 0.67 | 1157.73 | 1,822,347 | 2025-04-22 17:25:42 | 0% |
| Axis ELSS Tax Saver Fund | 1,426,357 | 2.7 | 906.16 | 1,426,357 | 2025-04-22 17:25:42 | 0% |
| Aditya Birla Sun Life Flexi Cap Fund | 950,000 | 3.08 | 603.53 | 950,000 | 2025-04-22 17:25:42 | 0% |
| HDFC ELSS Tax Saver Fund | 750,000 | 3.54 | 476.47 | 750,000 | 2025-04-22 17:25:42 | 0% |
| Nippon India Pharma Fund | 648,795 | 5.98 | 412.18 | 648,795 | 2025-04-22 17:25:42 | 0% |
| HDFC Focused 30 Fund - Regular Plan | 625,000 | 4.26 | 397.06 | 625,000 | 2025-04-22 17:25:42 | 0% |
| Axis Bluechip Fund | 622,060 | 1.21 | 395.19 | 622,060 | 2025-04-22 11:41:35 | 0% |
| Axis Focused 25 Fund | 593,270 | 2.72 | 376.9 | 593,270 | 2025-04-22 17:25:42 | 0% |
| UTI Nifty 50 ETF | 504,646 | 0.67 | 320.6 | 504,646 | 2025-04-22 17:25:42 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 100.56 | 62.50 | 56.97 | 73.42 | 10.74 |
| Diluted EPS (Rs.) | 100.56 | 62.50 | 56.97 | 73.42 | 10.74 |
| Cash EPS (Rs.) | 155.05 | 111.54 | 104.51 | 118.34 | 49.31 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 571.09 | 509.07 | 454.19 | 408.74 | 333.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 571.09 | 509.07 | 454.19 | 408.74 | 333.96 |
| Revenue From Operations / Share (Rs.) | 1515.58 | 1325.40 | 1155.25 | 1019.65 | 734.35 |
| PBDIT / Share (Rs.) | 224.07 | 173.64 | 148.81 | 157.39 | 82.22 |
| PBIT / Share (Rs.) | 171.39 | 125.87 | 106.02 | 115.62 | 42.37 |
| PBT / Share (Rs.) | 139.51 | 94.75 | 79.53 | 109.74 | 15.35 |
| Net Profit / Share (Rs.) | 102.37 | 63.77 | 61.72 | 76.57 | 9.46 |
| NP After MI And SOA / Share (Rs.) | 100.55 | 62.49 | 56.96 | 73.41 | 10.46 |
| PBDIT Margin (%) | 14.78 | 13.10 | 12.88 | 15.43 | 11.19 |
| PBIT Margin (%) | 11.30 | 9.49 | 9.17 | 11.33 | 5.76 |
| PBT Margin (%) | 9.20 | 7.14 | 6.88 | 10.76 | 2.08 |
| Net Profit Margin (%) | 6.75 | 4.81 | 5.34 | 7.50 | 1.28 |
| NP After MI And SOA Margin (%) | 6.63 | 4.71 | 4.93 | 7.19 | 1.42 |
| Return on Networth / Equity (%) | 17.60 | 12.95 | 13.21 | 18.77 | 3.26 |
| Return on Capital Employeed (%) | 15.32 | 14.97 | 13.73 | 15.38 | 6.49 |
| Return On Assets (%) | 6.99 | 5.36 | 5.67 | 8.00 | 1.31 |
| Long Term Debt / Equity (X) | 0.53 | 0.32 | 0.31 | 0.43 | 0.53 |
| Total Debt / Equity (X) | 0.64 | 0.45 | 0.43 | 0.46 | 0.54 |
| Asset Turnover Ratio (%) | 1.17 | 1.22 | 0.54 | 0.55 | 0.86 |
| Current Ratio (X) | 1.53 | 1.13 | 1.30 | 1.73 | 1.79 |
| Quick Ratio (X) | 1.43 | 1.03 | 1.19 | 1.55 | 1.66 |
| Inventory Turnover Ratio (X) | 46.34 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 18.89 | 24.00 | 31.15 | 4.13 | 25.46 |
| Dividend Payout Ratio (CP) (%) | 12.39 | 13.60 | 17.79 | 2.63 | 5.29 |
| Earning Retention Ratio (%) | 81.11 | 76.00 | 68.85 | 95.87 | 74.54 |
| Cash Earning Retention Ratio (%) | 87.61 | 86.40 | 82.21 | 97.37 | 94.71 |
| Interest Coverage Ratio (X) | 7.03 | 5.56 | 5.62 | 5.98 | 2.63 |
| Interest Coverage Ratio (Post Tax) (X) | 4.21 | 3.04 | 3.33 | 3.13 | 1.17 |
| Enterprise Value (Cr.) | 99584.27 | 93953.52 | 64237.57 | 66797.88 | 43713.80 |
| EV / Net Operating Revenue (X) | 4.57 | 4.93 | 3.87 | 4.56 | 4.14 |
| EV / EBITDA (X) | 30.91 | 37.63 | 30.02 | 29.51 | 36.97 |
| MarketCap / Net Operating Revenue (X) | 4.37 | 4.79 | 3.73 | 4.43 | 3.95 |
| Retention Ratios (%) | 81.10 | 75.99 | 68.84 | 95.86 | 74.53 |
| Price / BV (X) | 11.60 | 13.17 | 10.00 | 11.55 | 9.07 |
| Price / Net Operating Revenue (X) | 4.37 | 4.79 | 3.73 | 4.43 | 3.95 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
After reviewing the key financial ratios for Apollo Hospitals Enterprise Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 100.56. This value is within the healthy range. It has increased from 62.50 (Mar 24) to 100.56, marking an increase of 38.06.
- For Diluted EPS (Rs.), as of Mar 25, the value is 100.56. This value is within the healthy range. It has increased from 62.50 (Mar 24) to 100.56, marking an increase of 38.06.
- For Cash EPS (Rs.), as of Mar 25, the value is 155.05. This value is within the healthy range. It has increased from 111.54 (Mar 24) to 155.05, marking an increase of 43.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 571.09. It has increased from 509.07 (Mar 24) to 571.09, marking an increase of 62.02.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 571.09. It has increased from 509.07 (Mar 24) to 571.09, marking an increase of 62.02.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,515.58. It has increased from 1,325.40 (Mar 24) to 1,515.58, marking an increase of 190.18.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 224.07. This value is within the healthy range. It has increased from 173.64 (Mar 24) to 224.07, marking an increase of 50.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 171.39. This value is within the healthy range. It has increased from 125.87 (Mar 24) to 171.39, marking an increase of 45.52.
- For PBT / Share (Rs.), as of Mar 25, the value is 139.51. This value is within the healthy range. It has increased from 94.75 (Mar 24) to 139.51, marking an increase of 44.76.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 102.37. This value is within the healthy range. It has increased from 63.77 (Mar 24) to 102.37, marking an increase of 38.60.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 100.55. This value is within the healthy range. It has increased from 62.49 (Mar 24) to 100.55, marking an increase of 38.06.
- For PBDIT Margin (%), as of Mar 25, the value is 14.78. This value is within the healthy range. It has increased from 13.10 (Mar 24) to 14.78, marking an increase of 1.68.
- For PBIT Margin (%), as of Mar 25, the value is 11.30. This value is within the healthy range. It has increased from 9.49 (Mar 24) to 11.30, marking an increase of 1.81.
- For PBT Margin (%), as of Mar 25, the value is 9.20. This value is below the healthy minimum of 10. It has increased from 7.14 (Mar 24) to 9.20, marking an increase of 2.06.
- For Net Profit Margin (%), as of Mar 25, the value is 6.75. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 6.75, marking an increase of 1.94.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.63. This value is below the healthy minimum of 8. It has increased from 4.71 (Mar 24) to 6.63, marking an increase of 1.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 17.60. This value is within the healthy range. It has increased from 12.95 (Mar 24) to 17.60, marking an increase of 4.65.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.32. This value is within the healthy range. It has increased from 14.97 (Mar 24) to 15.32, marking an increase of 0.35.
- For Return On Assets (%), as of Mar 25, the value is 6.99. This value is within the healthy range. It has increased from 5.36 (Mar 24) to 6.99, marking an increase of 1.63.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.53. This value is within the healthy range. It has increased from 0.32 (Mar 24) to 0.53, marking an increase of 0.21.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 0.64, marking an increase of 0.19.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.17. It has decreased from 1.22 (Mar 24) to 1.17, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 1.13 (Mar 24) to 1.53, marking an increase of 0.40.
- For Quick Ratio (X), as of Mar 25, the value is 1.43. This value is within the healthy range. It has increased from 1.03 (Mar 24) to 1.43, marking an increase of 0.40.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 46.34. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 46.34, marking an increase of 46.34.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 18.89. This value is below the healthy minimum of 20. It has decreased from 24.00 (Mar 24) to 18.89, marking a decrease of 5.11.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 12.39. This value is below the healthy minimum of 20. It has decreased from 13.60 (Mar 24) to 12.39, marking a decrease of 1.21.
- For Earning Retention Ratio (%), as of Mar 25, the value is 81.11. This value exceeds the healthy maximum of 70. It has increased from 76.00 (Mar 24) to 81.11, marking an increase of 5.11.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 87.61. This value exceeds the healthy maximum of 70. It has increased from 86.40 (Mar 24) to 87.61, marking an increase of 1.21.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.03. This value is within the healthy range. It has increased from 5.56 (Mar 24) to 7.03, marking an increase of 1.47.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.21. This value is within the healthy range. It has increased from 3.04 (Mar 24) to 4.21, marking an increase of 1.17.
- For Enterprise Value (Cr.), as of Mar 25, the value is 99,584.27. It has increased from 93,953.52 (Mar 24) to 99,584.27, marking an increase of 5,630.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.57. This value exceeds the healthy maximum of 3. It has decreased from 4.93 (Mar 24) to 4.57, marking a decrease of 0.36.
- For EV / EBITDA (X), as of Mar 25, the value is 30.91. This value exceeds the healthy maximum of 15. It has decreased from 37.63 (Mar 24) to 30.91, marking a decrease of 6.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.37. This value exceeds the healthy maximum of 3. It has decreased from 4.79 (Mar 24) to 4.37, marking a decrease of 0.42.
- For Retention Ratios (%), as of Mar 25, the value is 81.10. This value exceeds the healthy maximum of 70. It has increased from 75.99 (Mar 24) to 81.10, marking an increase of 5.11.
- For Price / BV (X), as of Mar 25, the value is 11.60. This value exceeds the healthy maximum of 3. It has decreased from 13.17 (Mar 24) to 11.60, marking a decrease of 1.57.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.37. This value exceeds the healthy maximum of 3. It has decreased from 4.79 (Mar 24) to 4.37, marking a decrease of 0.42.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Apollo Hospitals Enterprise Ltd:
- Net Profit Margin: 6.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.32% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 17.6% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.43
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 63.6 (Industry average Stock P/E: 99.6)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.64
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.75%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | No.19, Bishop Gardens, Chennai (Madras) Tamil Nadu 600028 | investor.relations@apollohospitals.com https://www.apollohospitals.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Prathap C Reddy | Founder & Chairman |
| Mrs. Preetha Reddy | Executive Vice Chairperson |
| Mrs. Suneeta Reddy | Managing Director |
| Mrs. Sangita Reddy | Joint Managing Director |
| Mrs. Shobana Kamineni | Non Exe.Non Ind.Director |
| Mrs. V Kavitha Dutt | Independent Director |
| Dr. Murali Doraiswamy | Independent Director |
| Mrs. Rama Bijapurkar | Independent Director |
| Dr. Som Mittal | Independent Director |
| Mr. M B N Rao | Lead Independent Director |
FAQ
What is the intrinsic value of Apollo Hospitals Enterprise Ltd?
Apollo Hospitals Enterprise Ltd's intrinsic value (as of 27 November 2025) is 5932.12 which is 19.79% lower the current market price of 7,396.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,06,336 Cr. market cap, FY2025-2026 high/low of 8,100/6,001, reserves of ₹9,021 Cr, and liabilities of 21,950 Cr.
What is the Market Cap of Apollo Hospitals Enterprise Ltd?
The Market Cap of Apollo Hospitals Enterprise Ltd is 1,06,336 Cr..
What is the current Stock Price of Apollo Hospitals Enterprise Ltd as on 27 November 2025?
The current stock price of Apollo Hospitals Enterprise Ltd as on 27 November 2025 is 7,396.
What is the High / Low of Apollo Hospitals Enterprise Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Apollo Hospitals Enterprise Ltd stocks is 8,100/6,001.
What is the Stock P/E of Apollo Hospitals Enterprise Ltd?
The Stock P/E of Apollo Hospitals Enterprise Ltd is 63.6.
What is the Book Value of Apollo Hospitals Enterprise Ltd?
The Book Value of Apollo Hospitals Enterprise Ltd is 632.
What is the Dividend Yield of Apollo Hospitals Enterprise Ltd?
The Dividend Yield of Apollo Hospitals Enterprise Ltd is 0.26 %.
What is the ROCE of Apollo Hospitals Enterprise Ltd?
The ROCE of Apollo Hospitals Enterprise Ltd is 16.6 %.
What is the ROE of Apollo Hospitals Enterprise Ltd?
The ROE of Apollo Hospitals Enterprise Ltd is 18.4 %.
What is the Face Value of Apollo Hospitals Enterprise Ltd?
The Face Value of Apollo Hospitals Enterprise Ltd is 5.00.